DEENOVA
20.6.2022 06:02:09 CEST | Business Wire | Press release
Deenova today disclosed that it expanded its market dominance in France with another net new UniHA competitive award for its D3 ACCED mechatronic solution at Centre Hospitalier de Mayotte in French overseas departments. Additionally, Deenova announced a new competitive tender win at GHPSO Creil & Senlis also for its market leading D3 ACCED mechatronic robot through its partnership with another premier hospital group, RESAH . Separately, Deenova is pleased to simultaneously report additional add-on sales of its unique ASTUS cabinets and D3 ACCED to existing Deenova customer Institute Nationale des Invalides in Paris, also through its UniHA partnership.
Loïc Bessin , Managing Director of Deenova in France stated: “Bringing together net new business tender wins at Centre Hospitalier de Mayotte and GHPSO Creil & Senlis for our D3 ACCED mechatronic solutions, while at the same time earning the trust of additional sales to previous Deenova ASTUS customers such as Institute Nationale des Invalides is steady evidence of Deenova France unparalleled success in our industry, undoubtedly showing the market a high level of reliable customer satisfaction in France.”
Christophe Jaffuel , Deenova Chief Commercial Officer, added: “A new milestone for Deenova is reached: expansion beyond the European continent, a great ongoing incentive for our sales teams. I am very appreciative for the important and yearly contribution that both UniHA and RESAH ongoing multi-year tender awards means to Deenova in France and now beyond, renewing its past commitment to Deenova market-leading Unit-Dose solutions. I look forward to continuing the outstanding cooperation with UniHA and RESAH in the near future.”
Centre Hospitalier de Mayotte , a public health establishment with 543 beds, is the only hospital in the overseas Department of Mayotte . It is located in the northern part of the Mozambique Channel in the Indian Ocean off the coast of Southeastern Africa. It provides both hospital care and out-patient care with 4 localized care and childbirth centers (North, Centre, South and Petite-Terre) of intermediate level, providing general consultations and a 24-hour medical service and 7 days a week.
GHPSO Creil & Senlis , located just 30 minutes from Paris CDG airport , offers a complete emergency service: Adult, Paediatric and Gyneco-obstetrics with 584 full hospital beds, 46 day hospitalization places, 21 haemodialysis stations, and on the other hand an offer in Follow-up and Rehabilitation Care (SSR) with 32 beds, in accommodation with 73 Long-Term Care Unit beds (USLD), 90 beds in an Accommodation Establishment for Dependent Elderly Persons (EHPAD) and 12 places in Alzheimer's day centre, i.e. a total of 858 beds. The SMUR unit intervenes at the request of the SAMU de l’Oise.
Institute Nationale des Invalides is placed under the supervision of the French Government Ministry of Defense and Veterans Affairs. It is responsible for welcoming veterans who are victims of severe handicaps linked to war wounds. It includes three complementary centers: the Pensioners’ Center, the Post-Traumatic Rehabilitation Center and the Center for Studies and Research on Equipment for the Handicapped. A total of 91 single rooms are fully equipped for patients in the Paris metropolitan area.
UniHA , the Union of Hospitals for Purchasing, is a cooperative of French public hospital buyers created in 2005 by the hospital staff themselves (32 CHU and 20 CH). As of 2022, 1.065 hospitals have joined the UniHA cooperative, with 115 GHT having conducted € 5.6 billion in group purchases in 2021. UniHA is one of the main European buyers in the field of health and one of the first national buyers, all sectors of activity combined. The essential challenge: to provide citizens with the best treatments available, to provide high-quality hospital services, and to preserve equal access to care.
RESAH is a public interest group (GIP) whose objective is to support the pooling and professionalisation of purchases from the health sector, public and private non-profit. It was created in 2007 to support the pooling of hospital purchases for the Ile-de-France region, in collaboration with Achat Hopital.
Deenova is the undisputed leading supplier of combined mechatronics (robotic and automation) solutions for closed loop medications and RFID-based medical devices traceability in the healthcare industry, anytime and anywhere. Deenova ’s unique, patented, and fully integrated solutions have and will greatly contribute to ease healthcare providers’ growing pressures to: simultaneously improve patient safety, reduce therapy errors, minimise waste and controlled substance diversion, contain costs, and diminish the gap between rising patient volume/acuity and scarce medical staff. Deenova guarantees the simplification of all processes related to the management of medications and implantable/disposable medical devices with an expected cost savings range between 15% and 25%. Please visit www.deenova.com for additional information on its market leading solutions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220619005038/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche12.3.2026 21:50:00 CET | Press release
Estithmar Holding Q.P.S.C. has paid the third semi-annual coupon of its Qatari Riyal-denominated Sukuk (first tranche), at an annual profit rate of 8.75%. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260312880092/en/ Estithmar Holding Pays the Third Semi-Annual coupon of the 8.75% Sukuk Tranche (Photo: AETOSWire) The first tranche, part of the company’s broader Sukuk program valued at QAR 3.4 billion and listed on the London Stock Exchange’s International Securities Market, was issued in August 2024. The issuance attracted a diverse pool of institutional investors including banks, insurance companies, and asset managers, with strong interest from both government-affiliated and private institutions. This demand reflects growing investor confidence in Estithmar Holding’s ability to deliver sustained value to stakeholders. EstithmarHolding was recently included in the FTSE Russell Global Equity Index, in Qatar’s Mid-Cap segme
Andersen Consulting styrker sine kompetencer i samarbejde med Acumen Learning12.3.2026 21:36:00 CET | Pressemeddelelse
Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Acumen Learning, en amerikansk virksomhed, der specialiserer sig i træning i forretnings- og økonomiforståelse med henblik på lederudvikling og salgsresultater. Acumen Learning blev stiftet i 2002 og samarbejder med Fortune 500-virksomheder for en bedre finansiel forståelse, strategisk tænkning og beslutningstagning på alle niveauer. Med udgangspunkt i principperne fra deres bestsellerbøger "Seeing the Big Picture" og "Business Acumen for Sales Success" klæder deres programmer ledere og teams på til at afstemme beslutninger med virksomhedsstrategier, fremme resultater og styrke kunderelationer. Acumen Learning er målrettet brancher som sundhedssektoren, energi og teknologi og giver fagfolk mulighed for at omsætte forretningsviden til håndgribelige resultater. "Hos Acumen Learning er vores mission at styrke det enkelte menneske ved at skabe forretningskyndige fagfolk, der gør en forskel i deres karrierer," udtalte K
REPLY: The Board of Directors Approved the Draft Financial Statements for the Year 202512.3.2026 15:38:00 CET | Press release
All economic indicators are positive.Consolidated turnover of €2,483.6 million (€2,300.5 million in 2024);EBITDA at €467.6 million (€410.6 million in 2024);EBIT at €391.7 million (€330.4 million in 2024)Group net profit at €250.9 million (€211.1 million in 2024)Approval of the proposed dividend distribution of €1.35 per share. Today the Board of Directors of Reply S.p.A. [MTA, STAR: REY] approved the draft financial statement for the year 2025, which will be submitted for approval to the Shareholders’ Meeting to be held in first call in Turin on 23 April 2026. The Reply Group closed 2025 with a consolidated turnover of €2,483.6 million, an increase of 8.0% compared to €2,300.5 million in 2024. All indicators are positive for the period. Consolidated EBITDA was €467.6 million, an increase of 13.9% compared to €410.6 million at December 2024. EBIT, from January to December, was at €391.7 million, which is an increase of 18.5% compared to €330.4 million at December 2024. The Group net pro
LZE GmbH Introduces Fraunhofer’s RFicient® Technology to the Market12.3.2026 14:51:00 CET | Press release
LZE GmbH is expanding its technology transfer portfolio and making the RFicient® ultra-low-power wake-up receiver technology from the Fraunhofer Institute for Integrated Circuits IIS available for the first time as a standard chip for close-to-production industrial applications. The solution enables energy-efficient IoT designs that remain continuously reachable while consuming only microamps – a key step for long-lasting, low-maintenance IoT products. LZE GmbH drives technology transfer to market: standard chip availability for close-to-production applications As a bridge between research and industry, LZE GmbH is making it easier for companies to access innovative technologies and helping them to quickly and reliably transform new developments into market-ready solutions. With RFicient®-IC (FH101RF), LZE is providing another high-tech product that comes directly from Fraunhofer research and can now be ordered in volume and integrated into close-to-production product development for t
Owkin Creates New Spin out Waiv, Formerly Owkin Dx, With $33M Financing12.3.2026 14:30:00 CET | Press release
Investment lead by OTB Ventures and Alpha Intelligence CapitalWaiv develops AI-powered precision testing to better identify and stratify patients in the clinic and in clinical trials, transforming patient careWaiv extends Owkin’s strategy of real-world validation for its AI Owkin, the AI company on a mission to solve the complexity of biology, today announced the spin out of Waiv, formerly known as Owkin Dx. The move follows significant investor interest and positions Waiv to bring AI-powered precision testing for better identification of patients in the clinic and in clinical trials, to transform patient care. This follows on from the successful launch of Bioptimus, an Owkin incubated company, in February 2024. Waiv translates AI innovation into real-world clinical impact, developing tests that predict biomarkers and patient outcomes, including RlapsRisk BC for prognostic risk profiling. With multiple tests already in use in clinical settings, its deployment platform Destra, and colla
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
